

## TruScreen Share Placement

### ISSUE OF SECURITIES BY TRUSCREEN LIMITED (TRU)

TruScreen Limited advises that it has issued new unlisted options as follows:

<b>Class of Security:</b>	Unlisted options (TRUOA)				
<b>Number issued:</b>	9,000,000 unlisted options (TRUOA) exercisable at 15 cents per share before 27 August 2022				
<b>Payment:</b>	Nil				
<b>Percentage of total Class of Securities issued:</b>	TRUOA 45.7% (of the total number of unlisted share options on issue post completion of the issue)				
<b>Reason for the issue:</b>	Director and employee remuneration incentives				
<b>Authority of issue:</b>	Approved by shareholders at Annual Meeting held on 27 August 2019 Resolution 9.				
<b>Terms of issue:</b>	The unlisted share options are exercisable at 15 cents per share before 27 August 2022				
<b>Total number of securities of the Class in existence after the issue:</b>	<table><tr><td>TRU</td><td>227,534,804</td></tr><tr><td>TRUOA</td><td>19,677,363</td></tr></table>	TRU	227,534,804	TRUOA	19,677,363
TRU	227,534,804				
TRUOA	19,677,363				
<b>Date of issue:</b>	24 September, 2019				

**TRUSCREEN LIMITED**

**Guy Robertson**

**Chief Financial Officer**

-ENDS-

For more information visit [www.truscreen.com](http://www.truscreen.com) or contact Guy Robertson, TruScreen Chief Financial Officer, email: [guyrobertson@truscreen.com](mailto:guyrobertson@truscreen.com)

**About TruScreen:**

TruScreen's real time cervical cancer technology utilises a digital wand which is placed on the surface of the cervix to measure electrical and optical signals from the surrounding tissue. A sophisticated proprietary algorithm framework distinguishes between normal and abnormal (cancerous and precancerous) tissue to identify precancerous change, or cervical intraepithelial neoplasia (CIN). A Single Use Sensor (SUS) is used for each patient to protect against cross-infection.

